Drug Profile

Research programme: Escherichia coli vaccines - Syntiron

Latest Information Update: 22 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Syntiron
Class Escherichia coli vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Escherichia coli infections

Highest Development Phases

Preclinical Escherichia coli infections

Most Recent Events

22 Sep 2025 Escherichia coli vaccine is still in preclinical development for Escherichia coli infections (Prevention) in (USA) (Syntiron pipeline, September 2025)
28 Feb 2022 No recent reports of development identified for preclinical development in Escherichia-coli-infections in USA
23 Jan 2018 Escherichia coli vaccine - Syntiron is available for licensing as of 23 Jan 2018. http://syntiron.com/about-us/

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com